TREND Statement Checklist

Paper Section/	Item No	Descriptor	Reported?	
				D. 4
Topic			\square	Pg#
Title and Abstract				
Title and Abstract	1	Information on how unit were allocated to interventions	\square	NA
		Structured abstract recommended	$ \overline{\mathbf{Z}} $	3
		Information on target population or study sample	Ŋ	3
Introduction				
Background	2	Scientific background and explanation of rationale	\square	4
		Theories used in designing behavioral interventions	\square	NA
Methods	1	, , , , , , , , , , , , , , , , , , , ,		.
Participants	3	Eligibility criteria for participants, including criteria at different	\square	6
1		levels in recruitment/sampling plan (e.g., cities, clinics, subjects)		
		Method of recruitment (e.g., referral, self-selection), including	\square	6
		the sampling method if a systematic sampling plan was		
		implemented		
		Recruitment setting	\square	6
		Settings and locations where the data were collected	\square	7
Interventions	4	Details of the interventions intended for each study condition	\square	NA
		and how and when they were actually administered, specifically		
		including:		
		o Content: what was given?	V	NA
		o Delivery method: how was the content given?	\square	NA
		o Unit of delivery: how were the subjects grouped during	\square	NA
		delivery?		
		o Deliverer: who delivered the intervention?	V	NA
		o Setting: where was the intervention delivered?	Ø	NA
		o Exposure quantity and duration: how many sessions or	\square	NA
		episodes or events were intended to be delivered? How long		
		were they intended to last?		
		o Time span: how long was it intended to take to deliver the		NA
		intervention to each unit?		
		o Activities to increase compliance or adherence (e.g.,	\square	NA
		incentives)		
Objectives	5	Specific objectives and hypotheses	Ŋ	4
Outcomes	6	Clearly defined primary and secondary outcome measures	V	NA
		Methods used to collect data and any methods used to enhance	\square	8,9
		the quality of measurements		
		Information on validated instruments such as psychometric and	\square	8, 9
		biometric properties		
Sample Size	7	How sample size was determined and, when applicable,		NA
		explanation of any interim analyses and stopping rules		
Assignment Method	8	Unit of assignment (the unit being assigned to study condition,	\square	NA
		e.g., individual, group, community)		
		Method used to assign units to study conditions, including details	\square	NA

		of any restriction (e.g., blocking, stratification, minimization)		
		Inclusion of aspects employed to help minimize potential bias	\square	NA
		induced due to non-randomization (e.g., matching)		
Blinding (masking)	9	Whether or not participants, those administering the	\square	NA
		interventions, and those assessing the outcomes were blinded to		
		study condition assignment; if so, statement regarding how the		
		blinding was accomplished and how it was assessed.		
Unit of Analysis	10	Description of the smallest unit that is being analyzed to assess	\square	NA
		intervention effects (e.g., individual, group, or community)		
		If the unit of analysis differs from the unit of assignment, the	\square	NA
		analytical method used to account for this (e.g., adjusting the		1411
		standard error estimates by the design effect or using multilevel		
		analysis)		
Statistical Methods	11	Statistical methods used to compare study groups for primary	\square	10, 11
Statistical World		methods outcome(s), including complex methods of correlated		10, 11
		data		
		Statistical methods used for additional analyses, such as a	\square	10, 11
		subgroup analyses and adjusted analysis		10, 11
		Methods for imputing missing data, if used	Ø	NA
		Statistical software or programs used	\square	9, 11
		Sudsticut software of programs used		7, 11
Results				
Participant flow	12	Flow of participants through each stage of the study: enrollment,	Ø	NA
i articipant now	12	assignment, allocation, and intervention exposure, follow-up,		1111
		analysis (a diagram is strongly recommended)		
		o Enrollment: the numbers of participants screened for eligibility,	\square	6
		found to be eligible or not eligible, declined to be enrolled, and	W	
		enrolled in the study		
		o Assignment: the numbers of participants assigned to a study	\square	NA
		condition		INA
		Condition		
		o Allocation and intervention exposure: the number of	\square	NA
		participants assigned to each study condition and the number of		1111
		participants who received each intervention		
		o Follow-up: the number of participants who completed the	\square	6, 7
		follow-up or did not complete the follow-up (i.e., lost to		0, 1
		follow-up), by study condition		
		Tollow up), of staay contained		
		o Analysis: the number of participants included in or excluded	\square	7
		from the main analysis, by study condition		
		Description of protocol deviations from study as planned, along	Ø	NA
		with reasons		
Recruitment	13	Dates defining the periods of recruitment and follow-up	Ø	6, 7
Baseline Data	14	Baseline demographic and clinical characteristics of participants	Ø	12
Daseinie Data		in each study condition		
		Baseline characteristics for each study condition relevant to	Ø	NA
		specific disease prevention research		
		Baseline comparisons of those lost to follow-up and those	\square	NA
		retained, overall and by study condition	ت ا	
		Comparison between study population at baseline and target	\square	NA
		population of interest		1343
	1	population of interest]	

Baseline equivalence	15	Data on study group equivalence at baseline and statistical	\square	12, 13
Daseille equivalence	10	methods used to control for baseline differences	V	12, 13
Numbers analyzed	16	Number of participants (denominator) included in each analysis	\square	7
2.00.000		for each study condition, particularly when the denominators		
		change for different outcomes; statement of the results in		
		absolute numbers when feasible		
		Indication of whether the analysis strategy was "intention to	\square	NA
		treat" or, if not, description of how non-compliers were treated in		
		the analyses		
Outcomes and	17	For each primary and secondary outcome, a summary of results	\square	12
estimation		for each estimation study condition, and the estimated effect size		
		and a confidence interval to indicate the precision		
		Inclusion of null and negative findings	\square	12
		Inclusion of results from testing pre-specified causal pathways	\square	NA
		through which the intervention was intended to operate, if any		
Ancillary analyses	18	Summary of other analyses performed, including subgroup or	\square	
		restricted analyses, indicating which are pre-specified or		NA
		exploratory		
Adverse events	19	Summary of all important adverse events or unintended effects		
		in each study condition (including summary measures, effect		NA
		size estimates, and confidence intervals)		
DISCUSSION			T	_
Interpretation	20	Interpretation of the results, taking into account study	\square	13-15
		hypotheses, sources of potential bias, imprecision of measures,		
		multiplicative analyses, and other limitations or weaknesses of		
		the study		
		Discussion of results taking into account the mechanism by	\square	NA
		which the intervention was intended to work (causal pathways)		
		or alternative mechanisms or explanations		
		Discussion of the success of and barriers to implementing the	\square	NA
		intervention, fidelity of implementation		
		Discussion of research, programmatic, or policy implications	\square	NA
Generalizability	21	Generalizability (external validity) of the trial findings, taking	\square	13, 14
		into account the study population, the characteristics of the		
		intervention, length of follow-up, incentives, compliance rates,		
		specific sites/settings involved in the study, and other contextual		
0 117 11		issues		
Overall Evidence	22	General interpretation of the results in the context of current	\square	15
		evidence and current theory		